C
rohn's disease (CD) is a chronic refractory inflammatory bowel disease which involves transmural inflammation of the gastrointestinal tract, potentially causing stricture and fistula formation. 1 Since the introduction of anti-tumor necrosis factor (TNF)-alpha antibody agents, including infliximab (IFX) and adalimumab (ADA) for the medical treatment of CD, its management has been significantly improved. [2] [3] [4] Fistulizing disease represents an evolving, yet unresolved, issue for the management of CD. Fistula may affect approximately 20% to 50% of patients with CD in population-based studies. [5] [6] [7] IFX for fistulizing CD has been reported to be less effective 4, 8, 9 ; however, these studies mainly included patients with external fistulas (enterocutaneous and perianal). Internal fistulas (IF) connect the intestine with various organs or anatomical structures (e.g., enteroenteric, enterovesical, or enterovaginal), and anti-TNF agents are believed to be less efficacious for IF compared with external and perianal fistulas. 9 It is also important to note that anti-TNF treatment for IF may be associated with the risk of bowel obstruction, abscess, and other infectious complications. 10 Standard treatment of choice for IF has been surgery, [11] [12] [13] [14] despite there is no previous study precisely assessing outcomes of IF treated with anti-TNF agents according to clinical characteristics, such as its location, form, numbers, or treatment and so on.
In this study, we performed a multicenter retrospective cohort study to investigate the outcomes of anti-TNF treatment for IF in CD and predictive factors for the outcome with the sufficient sample size.
MATERIALS AND METHODS

Patient Population
Gastroenterologists and surgeons who participated in this retrospective multicenter study were directly contacted and asked by T.K. to report all cases of patients with CD with IF treated with anti-TNF therapy between January 2002 and November 2015.
Data were retrospectively collected and submitted to the Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital from 20 tertiary referral centers. Patient inclusion was performed using case report sheets completed by the IBD specialists or gastroenterologists of each institution. Obtained data were based on a prior defined protocol and case report sheets.
Collected data included a detailed report of the disease phenotype and history, and baseline status of CD according to the Montreal classification 15 and Crohn's Disease Activity Index (CDAI). 16 In addition, characteristics of IF (location, single or multiple tract, associated stricture), treatment (type and duration of anti-TNF agents and concomitant treatments) were also recorded. The choice of IFX or ADA was made by the treating gastroenterologist because of the retrospective nature of the study.
After treatment with anti-TNF therapy, the short-and longterm IF closure, development of complications such as an abdominal abscess, and a need for surgery were also recorded. All data were submitted by September 2016.
Endpoints and Definitions
IF-related surgery was defined as a primary endpoint, and a secondary endpoint was fistula closure.
IF was defined as a connection between the gastrointestinal tract and other visceral organs, including another part of the intestine (entero-entero fistula), bladder (enterovesical fistula), and vagina (enterovaginal) inside the abdominal cavity. IF was classified as single in cases of a unique fistulous tract and complex in cases of multiple (2 or more) tracts. IF closure was defined by the disappearance of flow through the fistula tracts or the complete separation of organs by the radiological imaging (computed tomography, magnetic resonance imaging/enterography [MRI/MRE], cystoscopy, barium study, or endoscopy).
Statistical Analysis
The x 2 test was used to compare the frequencies in the contingency tables. A Kaplan-Meier curve together with the log-rank test and the Cox proportional hazard model was used for the evaluation of survival-time analyses. The unconditional logistic regression model adjusted for sex and age was used to estimate the risk of fistula closure. Age adjustments were conducted with age categorized into 6 groups (,19, 20-29, 30-39, 40-49, 50-59, and 60 years old), each of which was coded as a binary variable (0, 1). CDAI categories were coded as ordinal categorical variables (0, 1, 2, and 3 for CDAI of 2150, 150-220, 220-450, and 450-, respectively). After univariate analysis, all the variables with P values less than 0.15 were considered in the subsequent multivariate analysis. Adjustments for multiple comparisons were not performed because this study was conducted under the exploratory context. All P values were 2 sided, and those less than 0.05 were considered statistically significant. All the statistical analyses were conducted using the statistical software, STATA ver.13 (STATA Corp., College Station, TX).
ETHICAL CONSIDERATIONS
The study was approved by the institutional ethics committees of each participating institution.
RESULTS
Characteristics of the Study Population
A total of 93 CD cases were included in the study, with a mean follow-up period of 1453 days. Baseline characteristics are shown in Table 1 . The mean age was 37.4 6 11.5 years. Duration of disease on introduction of anti-TNF agents is 6.3 years. Small intestinal involvement was present, and disease extent was shown as L1 (n ¼ 16), L2 (n ¼ 4), and L3 (n ¼ 73) according to the Montreal classification. 15 Anal and upper gastrointestinal involvements were present in 53 (57.0%) and 37 (40.7%) patients, respectively. More than half of the patients had moderately to severely active disease defined by CDAI .220.
Characteristics of fistula was single in 67 patients (72.0%), whereas the remainder (n ¼ 26, 28%) had complex draining fistulas. Of these fistulas, most were entero-entero/colonic (n ¼ 72, 77.4%), and others were enterovesical (n ¼ 16, 17.8%) or enterovaginal (n ¼ 5, 5.6%). Coexisting stricture as defined by the radiologist (,5 mm in diameter) was present in 55 (59.1%) patients. IFX or ADA was used in 69 (74.2%) and 24 patients (25.8%), respectively. Concomitant immunomodulators (IM) were used in 49 (52.7%) patients. There were no patients who have coexisting abscess. Outcomes evaluated for each endpoint are shown in Table 2 .
Need for Surgery
Surgery was eventually performed in 41 (44.1%) patients. Cumulative surgery rate was 17.7, 27.5, 37.3, and 47.2% at 1, 2, 3, and 5 years from the induction of anti-TNF agents, respectively. Reasons for surgery were stricture (n ¼ 18, 43.9%), IF itself (n ¼ 15, 36.6%), abscess (n ¼ 4, 9.8%), and perforation (n ¼ 1, 2.4%), and local symptoms (n ¼ 3, 7.3%). Surgical complications occurred in 7 of 41 (17.1%) patients, including 4 abscess formations, 2 surgical site infection, and 1 anastomotic leak.
We then tried to look into the risk factors for surgery ( the successful closure. Of 27 patients, 25 had fistula closure confirmed by imaging techniques such as contrast-enhanced computed tomography or MRI (n ¼ 6 and 1, respectively), computed tomography or MR enterography (n ¼ 1 and n ¼ 4, respectively), endoscopy (n ¼ 6), barium study (n ¼ 6), or cystoscopy (n ¼ 1), whereas 2 patients were confirmed during surgery. Sustained closure of IF was objectively confirmed by imaging (n ¼ 22) or surgery (n ¼ 1) during their course, while 2 entero-entero fistulas were followed up only clinically.
Complications
Complications occurred in 16 patients (17.2%), including abscess formation (n ¼ 10), bowel obstruction (n ¼ 4), and exacerbation of IF (n ¼ 2). Of these 10 patients with abscess formation, 8 eventually required surgery and only 1 patient responded to the medical treatment for the abscess. Development of complications was associated with complex fistula (OR 6.778, P ¼ 0.001) and ADA (OR 5.229, P ¼ 0.004) by univariate analysis and ADA remained significant by multivariate analysis (OR 4.41, P ¼ 0.023) (see Table 2 , Supplemental Digital Content 1, http:// links.lww.com/IBD/B649).
Anti-TNF agents were discontinued in 12 patients (14.5%) mostly because of the complications mentioned above.
DISCUSSION
Here, we demonstrate real-world experience from a multicenter retrospective cohort on the outcome of IF treated by anti-TNF agents in CD with the largest number of patients. In general, surgical treatment has been a standard in treating IF because previous evidence was insufficient in helping in the decision making of whether or not each IF could be treated with medical therapy. [11] [12] [13] 17 Our data demonstrated that complete closure was confirmed in 29% of patients within the follow-up period, with a 5-year cumulative closure rate being 27.0%. It is also worthy of note that a 5-year cumulative surgery rate was 47.2%; in other words, more than half of the patients who had IF on the initiation of anti-TNF agents were maintained without surgery for 5 years in this group of patients.
It has been an unresolved dilemma between medical and surgical therapies when treating IF in CD, similar to intraabdominal abscess. 18 Attempt to treat IF with medical therapy has been reported since many years ago. The potential benefit of 6-mercaptopurine in treating IF was reported in 1985, 19 followed by a few case reports demonstrating the successful closure of enterovesical fistulas by IFX. 20, 21 Another report with 108 fistulizing CD patients including 12 patients with IF showed that complete response was achieved in 40% and 68% of enterovesical and enterovaginal fistulas, respectively; however, the follow-up period was only for 4 weeks. 22 A post hoc analysis of ACCENT II (A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-term Treatment Regimen in Patients With Fistulizing Crohn's Disease) evaluated the efficacy of IFX for a total of 27 rectovaginal fistulas and demonstrated that 44.8% of fistulas were closed at week 14 and better maintained by IFX, 23 although its long-term outcome, especially maintenance without need for surgery, remained unclear. 8 On the contrary, there is a case series of Fistula closure was confirmed in 27 (29.0%) patients, and univariate and multivariate analyses were conducted by logistic regression analysis (adjusted for age and sex in the multivariate analysis). Thirteen patients of whom the outcome was unknown or unexamined were excluded from the analysis.
4 patients with IF concluding that IFX was not effective for IF. 24 Recently, Taxonera et al reported that use of anti-TNF agents was associated with the successful treatment without surgery in patients with enterourinary fistula and 45% achieved sustained remission, while more than 80% of all cases required surgery. 25 There is no study investigating the outcomes of enteroenteric fistula treated with anti-TNF agents. Our data also demonstrated the outcome of surgery as a second-line of treatment after the initial anti-TNF agents. IF was shown to be indeed refractory to anti-TNF agents in CD because IF was still left unsolved in 71% of the patients. Reasons why surgery has been previously considered as the first choice for CD complicated with IF are not only because of the poor response but also the risk of complication. A total of 16 patients (17.2%) developed IF-related complications during the follow-up period, including abscess formation in 10 patients. This may suggest that surgery might have been a more appropriate treatment of choice than medical treatment with anti-TNF agents for those patients, and in fact, 8 of these 10 patients eventually required surgery for the abscess. Notably, only 1 of 8 suffered from postsurgical complications (abscess); therefore, initial anti-TNF therapy did not seem to ultimately lead to the poor surgical outcome even in those patients who suffered from the complication of anti-TNF agents. These results suggest that initial attempt with anti-TNF agents is still acceptable, and most cases could be successfully treated with a second-line surgery when anti-TNF agents fail.
IFX and ADA are the most widely used 2 anti-TNF antibodies for CD. Singh et al reported results from a retrospective analysis of a large cohort of biologic-naive patients with CD showing that IFX is superior to ADA for CD-related hospitalization. 26 Another group also demonstrated that fistula-related hospitalizations were less in patients treated with IFX compared with ADA. 27 Our study suggests that IFX may be superior to ADA, by multivariate analyses of risk factors for development of complications, which may be consistent with the previous literature, although these are all retrospective studies and the number of patients treated with ADA was small in our study. In addition, 8 of 24 patients treated with ADA had a history of anti-TNF treatment, which may be potentially related to the difference between IFX and ADA. Although the history of anti-TNF treatment was not statistically associated with development of complications (data not shown), it is still possible that ADA-treated group tended to be already more refractory to anti-TNF therapy than the IFX-treated group.
Complex fistula was also identified as a risk factor for developing complications, and concomitant use of IM was shown to be protective from IF-related surgery by multivariate analyses. Therefore, taken together, it would be reasonable to start with the medical therapy by anti-TNF agents in combination with IM for the patients with low CDAI complicated by single fistula rather than to immediately conduct surgery, although it may eventually require surgery if the initial medical treatment fails.
This study has some limitations. We retrospectively collected the data only from patients who were treated with anti-TNF agents. Therefore, our study does not include patients for whom physicians recommended immediate surgery with probably more severe diseases. This may be a potential selection bias and might have overestimated the actual efficacy of anti-TNF agents. There may also be a selection bias between IFX versus ADA, as physicians may tend to choose IFX for severe CD. The other possibility is an information bias for endpoints. We strictly defined the diagnosis of IF closure that had to be confirmed by the objective method including radiological images or endoscopy. However, it is not uncommon that IF is asymptomatic and objectively confirming the fistula closure by imaging modalities may be difficult. Therefore, it is possible that the patients with IF who responded to anti-TNF agents were judged as closed later than the actual timing of its closure, or even defined as no change because of the overall symptom independent of IF. This might have led to the underestimation of the efficacy on IF closure. In addition, the whole group of patients might have included the patients who strongly refused the recommendation for surgery, which might have remained the same and kept the patients from surgery over the entire follow-up period.
In summary, we demonstrated the real-world overall efficacy of anti-TNF agents for IF in CD by the multicenter cohort study with the sufficient sample size. Lower CDAI, shorter duration from the diagnosis of IF, single fistula, IFX, and concomitant use of IM seemed to be protective from the risk of fistula-related surgery and other clinically relevant outcomes. Well-designed prospective studies are needed to confirm our results.
